Clinical-stage biopharmaceutical company
Medicines designed from human data, not from guesswork.
DataCram Therapeutics starts every program with human genetics. Our platform nominates targets that patient data says are causal, then designs candidates against them — so the biology is de-risked before a molecule exists.
- 5
- Programs in development
- 2
- In clinical studies
- 80+
- Scientists and staff
Pipeline
Five programs, four modalities, one source of biology.
Every program below traces to a target our platform nominated from human data. Stage reflects development status only.
| Program | Target | Indication | Modality | StageDiscINDPh 1Ph 2Ph 3 |
|---|---|---|---|---|
| DCT-101 | IRAK4 | Moderate-to-severe atopic dermatitis | Oral small molecule | Phase 2 |
| DCT-204 | STING | Advanced solid tumors | Small molecule agonist | Phase 1 |
| DCT-311Partnered — undisclosed | αvβ6 integrin | Idiopathic pulmonary fibrosis | Inhaled peptide | IND-enabling |
| DCT-408 | TREM2 | Early Alzheimer's disease | Monoclonal antibody | IND-enabling |
| DCT-5xx | Undisclosed | Autoimmune — undisclosed | Oral small molecule | Discovery |
Moderate-to-severe atopic dermatitis
Oral small molecule · Lead program; once-daily oral.
Advanced solid tumors
Small molecule agonist · Dose escalation in biomarker-selected patients.
Idiopathic pulmonary fibrosis
Inhaled peptide · Lung-restricted delivery.
Early Alzheimer's disease
Monoclonal antibody · Brain-penetrant format.
Autoimmune — undisclosed
Oral small molecule · Platform-derived; target nominated 2025.
Fictional programs, shown for demonstration. No clinical results, safety data, or trial registry identifiers appear anywhere on this page — and please do not ask your doctor about DCT-101.
Platform
The whole platform, in four steps.
If a partner cannot redraw your platform on a whiteboard after one visit, the page has failed. This is the entire mechanism.
Human data in
Paired genomic, transcriptomic, and clinical data from patient cohorts — not cell lines.
Target nomination
Causal models rank targets by how strongly human genetics ties them to the disease.
Candidate design
Structure-guided chemistry and biologics design against the nominated target.
Translational readout
Biomarker strategy defined before the first dose, so every study answers a question.
Why start with human genetics
Targets supported by human genetic evidence have historically been substantially more likely to survive clinical development than those chosen from cell or animal models alone. That single filter is the reason our discovery engine begins with patient cohorts rather than a screening library.
It also shapes how we run studies. Because the biology is chosen from human data, the biomarker is usually obvious before the protocol is written — so a Phase 1 answers a real question instead of only establishing tolerability.
Science
We publish, and we show our work.
Peer review is the only credential this audience fully trusts. Publications, posters, and preprints belong on the site — findable, dated, and linked to the program they support.
- 2026Causal target nomination from paired transcriptomic and clinical data in inflammatory skin diseasePeer-reviewed journal · manuscript accepted
- 2025Structure-guided optimization of a selective IRAK4 inhibitor seriesMedicinal chemistry journal
- 2025An inhaled αvβ6-targeting peptide reduces fibrotic burden in preclinical modelsRespiratory research journal
- 2024Benchmarking causal inference methods for target discovery across four disease cohortsPreprint server
Company
The team is part of the diligence.
Investors and partners want to know who has taken a molecule this far before. Named leadership with real histories, and a scientific advisory board that is more than a logo wall.
Diane Whitaker
Chief Executive Officer
Alan Brenner
Chief Scientific Officer
Priya Raghavan
Chief Medical Officer
Marcus Bell
Chief Business Officer
Daniel Park
SVP, Translational Medicine
Helen Marsh
SVP, Chemistry
These people are not real. The names are invented and the portraits are AI-generated — no biographies or credentials are claimed for any of them.
News
Momentum, dated and public.
A newsroom that has not been touched in eighteen months reads as a company in trouble. This section exists to be kept current.
- July 22, 2026Press releaseDataCram Therapeutics doses first patient in Phase 2 study of DCT-101 in atopic dermatitis
- June 4, 2026PublicationMulti-omic target nomination in inflammatory skin disease — peer-reviewed manuscript accepted
- May 12, 2026PresentationPreclinical characterization of DCT-311, an inhaled αvβ6 peptide, presented at a scientific congress
- March 2, 2026Press releaseCompany appoints new Chief Medical Officer and expands translational research group
Business development
Partnering, licensing, and investment.
One named route in for partners, one for investors, one for media. A single generic contact form is where biotech BD conversations go to die.
Partnering
bd@ — routed to the CBO
Investors
ir@ — routed to the CFO
Media
press@ — routed to comms
Addresses shown are illustrative and do not resolve.
End of demonstration
Everything above is a build we can ship for your company.
Real pipeline data, real publications, your programs and your team — on a fast, accessible site that holds up in front of investors, partners, and regulators. DataCram builds these on Next.js with a CMS your team can actually run.